Cystinuria Clinical Trial
Official title:
Open Label, Multicentre Study, Evaluating the Safety, Tolerability, Efficacy, Compliance and Acceptability of Alkalising Treatments at Long-term in Patients With Cystinuria
This is an open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and acceptability of alkalising treatments at long-term in patients with cystinuria.
B14CS study is an extension study which follows the B12CS-B13CS study. Patients who have participated in B12CS-B13CS Study will have the possibility to switch to B14CS Study for a long-term treatment period (2 year-period). The B14CS Study is an open-label long-term study and including 2 types of cohorts. - ADV7103 Cohort: Cohort of patients who will have completed either B12CS or B13CS Study. Following an optional titration period (for B12CS Study subjects), all patients will be maintained at their ADV7103 optimal dose for a 2-year-period. - SoC Cohort: Cohort of patients with cystinuria, matching-pair for age category to the patients of ADV7103 Cohort, will receive their own alkalinising treatment (SoC) taken at the usual dose and frequency and will follow their usual first intention treatment (hydration and diet) for a 2-year-period. This cohort is designed in order to contextualize the safety, tolerability and efficacy of the long-term ADV7103 treatment. The B14CS Study will be composed of 3 periods (more detailed hereafter): - Lead-in Period: Period of 3 weeks, during which the treatment (ADV7103 or SoC) will be taken at the optimal dose as previously defined (Maintenance Phase). The Lead-in Period can include a Titration Phase, for ADV7103 B12CS Cohort only, in order to define the individual optimal dose of ADV7103 for the patients of this cohort; - Assessment Period: Period of 7 days to evaluate the effect of study products (ADV7103 and SoC) at the optimal dose; - Follow-up Period: Period of 23 months to evaluate the effects of the study products (ADV7103 and SoC) at long-term. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02120105 -
Cystine Capacity Clinical Study (CysCap)
|
||
Completed |
NCT02538016 -
TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study
|
N/A | |
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Recruiting |
NCT00169806 -
Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis
|
N/A | |
Completed |
NCT03663855 -
Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria
|
Phase 2 | |
Recruiting |
NCT02780297 -
Prospective Research Rare Kidney Stones (ProRKS)
|
||
Recruiting |
NCT02026388 -
Rare Kidney Stone Consortium Biobank
|
||
Recruiting |
NCT04818034 -
The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
|
Phase 2 | |
Recruiting |
NCT02942420 -
Bucillamine Phase 2 Trial in Patients With Cystinuria
|
Phase 2 | |
Completed |
NCT05048563 -
Registry of Thiola EC Therapy
|
||
Not yet recruiting |
NCT04147871 -
Study Evaluating Patients With Cystinuria and Efficacy and Safety Exploratory Study in the Youngest Children
|
Phase 2/Phase 3 | |
Completed |
NCT02125721 -
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria
|
Phase 4 | |
Active, not recruiting |
NCT02910531 -
Lipoic Acid Supplement for Cystine Stone
|
Phase 2 | |
Recruiting |
NCT00588562 -
Rare Kidney Stone Consortium Patient Registry
|
||
Completed |
NCT02124395 -
Health-related Quality of Life in Rare Kidney Stone
|
||
Not yet recruiting |
NCT05058859 -
Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics
|
Phase 2 | |
Active, not recruiting |
NCT03539926 -
This Study Evaluates the Superiority of Daily Self-pH Monitorization of Lit-control®pH Meter Compared to the Monitorization of Reactive Strips (Standard of Care).
|
N/A | |
Completed |
NCT00381849 -
Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones
|
Phase 1/Phase 2 | |
Completed |
NCT03836144 -
Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria
|